Effect of Denosumab and Alendronate on glucocorticoid-induced osteoporosis in patients with glomerulonephritis:a randomized controlled trial
Not Applicable
- Conditions
- Glucocorticoid-Induced Osteoporosis
- Registration Number
- JPRN-UMIN000019574
- Lead Sponsor
- Showa University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who are considered to be contraindicated for denosumab. 2) Patients who are considered to be contraindicated for alendronate. 3) Cancer patients. 4) Patients who have pretreated with bisphosphonate in recent 6 months. 5) Patients who have pretreated with denosumab in recent 6 months. 6) Patients whose eGFR is less than 35ml/min/1.73m2. 7) Patients whose i-PTH is more than 300ml/min. 8) Patients whose corrected Ca is less than 8.4 mg/dL. 9) Patients who are thought to be inappropriate for this study by physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method